Evercore ISI initiated coverage of RayzeBio with an Outperform rating without a price target. The company has a full radiopharma platform with multiple programs as well as serious investments into manufacturing, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RYZB:
- William Blair biotech analyst to hold an analyst/industry conference call
- Truist starts RayzeBio at Buy on favorable risk/reward into data
- RayzeBio initiated with a Buy at Truist
- RayzeBio initiated with an Overweight at JPMorgan
- RayzeBio initiated with a Buy at Jefferies
Questions or Comments about the article? Write to editor@tipranks.com